Avandia Articles
GSK faces US class action law suit over Avandia
18 June 2007
Stock Commentary - Europe - week to June 4, 2007
11 June 2007
US Congress probes FDA on Avandia concerns
11 June 2007
FDA opts for standard review of Cervarix
11 June 2007
Stock Commentary - Europe - week to May 28, 2007
4 June 2007
GSK: new data will support Avandia safety
4 June 2007
Stock Commentary - Europe - week to May 21, 2007
28 May 2007
GSK shares slide 5.1% after Avandia linked to CV death risk; firm likely to cut guidance
28 May 2007
Diabetes remedy denounced as "unjust"
7 May 2007
GSK posts solid results for 1st-qtr 2007 with a 14% EPS rise despite US generic pressure
30 April 2007
Japan stock market week to March 19, 2007
26 March 2007
Mixed results from animal studies of CLA
5 March 2007
GSK alerts US prescribers to Avandia problems
26 February 2007
GSK's full-year 2006 turnover up 7%
12 February 2007
Study: GSK's Avandia cuts health care costs
7 February 2007
Canada: new formulary for new year - Ontario introducing reform
15 January 2007
Stock Commentary - Europe - week to Sept 25, 2006
2 October 2006
Stock Commentary - Europe - week to Sept 18, 2006
25 September 2006
DREAM study results position GSK's Avandia as first-line treatment for type 2 diabetes
25 September 2006
Takeda's sales reach $2.9B for 1st-qtr 2007
14 August 2006
Novartis' Galvus overcomes poor glycemic control
19 June 2006
Strong data for GSK's Avandaryl
13 June 2006
Development of B-MS' Pargluva discontinued
29 May 2006
GSK launches Avandaryl in USA
6 February 2006
Japan stock market week to September 5
12 September 2005
GSK EPS rises 10% on 6% sales growth
8 August 2005
GlaxoSmithKline sees 10% EPS rise on 6% sales growth
1 August 2005
Japan stock market week to July 4
11 July 2005
GSK's Paxil returns to US market
4 July 2005
GSK's Avandia may help lower blood pressure
20 June 2005
Australian PBS new Rx listings aimed at seniors
11 April 2005
GlaxoSmithKline's R&D pipeline looks set to drive near-term growth
21 February 2005
SCOLR Pharma files provisional patent for rosiglitazone
10 January 2005
EC OKs new dosage strengths of GSK's Avandamet
20 September 2004
GSK gives up on one Avandia formulation patent in China
23 August 2004
Israel: complaints over funds' drug access
23 August 2004
GSK's 2nd-qtr 2004 EPS drops 12%
2 August 2004
Avandia may reduce diabetes in ethnics
14 June 2004
Teva says GSK patent on Avandia invalid
10 May 2004
Tokyo pharma stocks - week to April 26
3 May 2004
GSK results in line with company guidance; shares fall on 16% drop in 4th-qtr income
23 February 2004
Tokyo pharma stocks - week to Jan 12
19 January 2004
EU approval for GSK's Avandamet
3 November 2003
GlaxoSmithKline reports 24% 3rd qtr earnings growth
27 October 2003
New indications for three GlaxoSmithKline products
8 September 2003
Takeda/Lilly's Actos OKed in EU as diabetes monotherapy
8 September 2003
GSK 2nd-qtr earnings beat forecasts
28 July 2003
Stock Commentary - Europe
30 June 2003
FDA reviewing GSK's Paxil safety
30 June 2003
GSK's Avandia cleared for use with insulin
10 March 2003
Tularik to commence diabetes study
3 February 2003
Sankyo to help GSK sell Avandia in Japan
3 February 2003
Analysts see threat to Novartis' Lotrel
6 January 2003
GSK drops Avandia deal with B-MS
12 August 2002
Avandia may impact heart risk factors
24 June 2002
Tokyo pharma stocks - week to May 6
13 May 2002
Glitazones raising risk of heart failure?
1 April 2002
Funding and approving new drugs in Israel's NHI basket
18 February 2002
GlaxoSmithKline 2001 pretax exceeds forecasts
18 February 2002
Patent ruling boosts Pakistani pharma
18 February 2002
GSK files Avandia in Japan
18 February 2002
French pharma points to innovations
12 December 2001
GlaxoSmithKline warned over Avandia promotion by US FDA
6 August 2001
Novartis and Novo join to market NN622
23 July 2001
GSK restructuring its R&D to boost productivity
22 February 2001
GlaxoSmithKline starts life in 2001 on a strong financial footing
21 February 2001
HOPE sub-study backs up ramipril benefit
20 February 2001
40%-123% US Rx price variations found
13 February 2001
FDA backs Avandia combo therapy
12 February 2001
SB to take Indian firms to court over Avandia?
5 December 2000
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
